| 左莉莉,陈 辉,秦振英,管亚飞,陈筱青.部超声在新生儿呼吸窘迫综合征临床诊断及肺泡表面活性物质治疗效果评估中的应用价值[J].,2020,(19):3678-3682 |
| 部超声在新生儿呼吸窘迫综合征临床诊断及肺泡表面活性物质治疗效果评估中的应用价值 |
| The Application Value of Pulmonary Ultrasound in Clinical Diagnosis of Neonatal Respiratory Distress Syndrome and Evaluation of Therapeutic Effect of Pulmonary Surfactant |
| 投稿时间：2020-03-06 修订日期：2020-03-30 |
| DOI：10.13241/j.cnki.pmb.2020.19.015 |
| 中文关键词: 新生儿呼吸窘迫综合征 肺部超声 肺泡表面活性物质 肺部超声评分 应用价值 |
| 英文关键词: Neonatal respiratory distress syndrome Pulmonary ultrasound Pulmonary surfactant Pulmonary ultrasound score Application value |
| 基金项目:江苏省妇幼健康科研项目（F201745） |
|
| 摘要点击次数: 753 |
| 全文下载次数: 504 |
| 中文摘要: |
| 摘要 目的：研究肺部超声在新生儿呼吸窘迫综合征（NRDS）临床诊断及肺泡表面活性物质（PS）治疗效果评估中的应用价值。方法：将我院于2018年6月～2020年3月期间诊治的80例NRDS患儿纳入研究，记作NRDS组。另取同期80例健康新生儿作为对照组。对所有新生儿进行系统的肺部超声检查并评分，并比较NRDS组和对照组检查结果。将NRDS患儿根据胎龄的不同分成＜30周亚组以及≥30周亚组，比较两组肺部超声检查结果。此外，将所有NRDS患儿按照是否接受PS治疗分成治疗组与非治疗组，比较两组肺部超声评分。结果：NRDS组肺实变、胸膜线异常、支气管充气征、融合B线、肺泡间质综合征、胸腔积液人数占比均高于对照组（均P＜0.05）。胎龄<30周亚组肺泡间质综合征人数占比低于胎龄≥30周亚组患儿，而胸腔积液人数占比高于胎龄≥30周亚组患儿（均P＜0.05）。治疗组治疗后12 h、24 h时的肺部超声评分分别为（15.23±3.15）分、（11.37±2.01）分，均低于非治疗组的（19.45±3.28）分、（16.48±2.83）分（均P＜0.05）。结论：肺部超声作为无创且实时监测手段，诊断NRDS的临床价值较高，且肺部超声评分可作为有效评估NRDS患儿接受PS治疗效果的指标，具有较好的临床应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To study the application value of pulmonary ultrasound in clinical diagnosis of neonatal respiratory distress syndrome (NRDS) and evaluation of therapeutic effect of pulmonary surfactant（PS）. Methods: 80 children with NRDS treated in our hospital from June 2018 to March 2020 were included in the study, and were labeled as NRDS group. Another 80 healthy newborns in the same period were selected as the control group. All newborns were systematically examined and scored by pulmonary ultrasound, and the results of NRDS group and control group were compared. According to different gestational ages, children with NRDS were divided into < 30 weeks subgroup and ≥30 weeks subgroup, and pulmonary ultrasound results of the two groups were compared. In addition, all children with NRDS were divided into treatment group and non-treatment group according to whether they had received PS treatment, and pulmonary ultrasound scores of the two groups were compared. Results: Lung consolidation, pleural abnormalities, air bronchi sign, fuse B-line, alveolar interstitial syndrome and pleural effusion in NRDS group were all higher than those in the control group (All P＜0.05). The proportion of children with alveolar interstitial syndrome in the gestational age <30 weeks subgroup was lower than that in the gestational age ≥30 weeks subgroup, while the proportion of patients with pleural effusion was higher than that in the gestational age ≥30 weeks subgroup(all P＜0.05). The pulmonary ultrasound scores of the treatment group at 12 h and 24 h after treatment were (15.23±3.15) scores and (11.37±2.01) scores, respectively, which were lower than that of the non-treatment group (19.45±3.28) scores and (16.48±2.83) scores (all P＜0.05). Conclusion: Pulmonary ultrasound has a high clinical value in diagnosing neonatal NRDS, and pulmonary ultrasound score can be used as an effective indicator to evaluate the effect of PS treatment in children with RDS. It is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
